Home » In Vivo models » Digestive System Disease Models
Digestive System Disease Models for Preclinical Research
Digestive System Disease Models
Digestive System Disease Models
Understanding digestive system disorders requires translationally relevant preclinical models that replicate human gastrointestinal (GI) conditions with precision. At Medicilon, we offer a comprehensive portfolio of rodent-based digestive disease models to support drug development for gastric ulcers, colitis, GI dysmotility, and related conditions.
Our models enable researchers to study disease mechanisms, therapeutic efficacy, and pharmacological responses in a controlled and clinically aligned environment. Designed for both exploratory research and IND-enabling studies, these models deliver reliable, decision-enabling data to accelerate GI therapeutic programs.
Clinically Aligned Models
Designed to mimic human GI disorders, from acid hypersecretion to inflammatory bowel disease.
Integrated Capabilities
End-to-end support including biomarker evaluation, pathology analysis, and pharmacodynamics.
Customized Protocols
Tailored to your compound’s mechanism of action and therapeutic targets.
Responsive, Expert-Driven Support
Dedicated study design, execution, and interpretation led by veteran pharmacologists and GI specialists.
Extensive Digestive Disease Model
At Medicilon, we go beyond standard modeling. we deliver scientifically rigorous, customizable solutions that help de-risk early-stage and IND-enabling development.
Rodent Digestive Disease Model Portfolio
Model Type
Disease Area
Models
- Model of pylorus ligation-induced gastric acid secretion and gastric ulcer
Rat
- Histamine-induced gastric acid secretion model
Rat
- Model of gastric ulcer caused by ethanol
Mouse/Rat
- Model of gastric ulcer induced by non-steroidal anti-inflammatory drugs
Rat
- Model of gastric ulcer induced by water bundle stress
Rat
- Acetic acid-induced gastric ulcer model
Rat
- Cysteine-induced duodenal mucosal ulcer model in rats
Rat
- Reflux esophagitis model
Rat
- TNBS-induced ulcerative colitis (cellular immunoassay)
Rat
- Ulcerative colitis caused by DNBS (cellular immunoassay)
Rat
- Ulcerative colitis model by DSS drinking method
Mouse
- Gastric emptying (carbon meal method)
Mouse/Rat
- Intestinal dynamics measurement
Mouse/Rat
- Functional dyspepsia
Rat
- Diarrhea model
Mouse
Supporting Discovery in Gastrointestinal Therapeutics
Whether you’re developing anti-ulcer agents, anti-inflammatory compounds, or gut motility modulators, Medicilon’s digestive system disease models offer the translational power and scientific depth to move your program forward
Tumor Models
Non-tumor Models
cancer therapy INNOVATION
Beyond Orthotopic Models, A Full-Spectrum Oncology Research Suite
Tumor models:
Medicilon provides a comprehensive range of oncology models, including:
- CDX Models – Fast, reliable tumor models for early-phase drug screening.
- PDX Models – Clinically relevant models for personalized medicine research.
- Syngeneic Mouse Models – Immunocompetent tumor models for evaluating novel cancer therapies in a controlled setting.
- Humanized Mouse Models – Bridge the gap between preclinical and clinical immunotherapy studies.
This holistic approach ensures that researchers can seamlessly transition from early drug discovery to translational research, accelerating the path to clinical trials.
In Vitro Assays for Early Stage Discovery
Complementing our in vivo models, Medicilon offers predictive in vitro systems that bridge bench-to-bedside.
With deep expertise in custom assay development, we work closely with clients to design solutions that align with their mechanism of action, disease biology, and development goals.
- Target Discovery & Validation:
- Using CRISPR, RNAi, and gene editing in human or rodent cell models.
- High-Throughput Phenotypic Assays:
- Including high-content imaging, bioenergetics profiling, and Seahorse analysis.
- Screening Across Modalities:
- Supporting small molecules, biologics, peptides, oligonucleotides, and mRNA therapeutics.
- Biomarker Discovery:
- Employing omics technologies such as metabolomics, lipidomics, and proteomics for translational insights.